Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good Post. Good deduction analysis.
OTCPennyPincher Wednesday, 03/08/17 04:06:58 PM
Re: Prince Goro post# 23739
Post #
23740
of 23761 Go
They just announced they retained a PCAOB auditor. You don't spend 40-50 grand on an auditor unless the business you are wanting to conduct calls for it. The merger or acquisition that's coming has to be very good.
This also means that the CEO's cigar venture must have been successful otherwise he wouldn't have that kind of money to be able to bring the merger in. He alluded to moving into the "hottest sector" and we all know he's a smoker..... so the assumption is that it's a MAJOR acquisition because he's spending 40-50 grand to become FULLY REPORTING WITH THE SEC. and that it's in the MJ sector because it's the hottest sector.
For all the new and returning investors on this board.
Here's a good article. I posted this on the board back in the beginning of Jan 2017.
http://www.transparencymarketresearch.com/cigars-cigarillos-market.html
Global Cigars & Cigarillos Market: Regional Outlook
Regionally, North America held the largest share of the market in 2014. Rising demand in the U.S. is expected to present favorable growth opportunities in the cigars and cigarillos market in North America.
The market in Asia Pacific is also expected to witness significant growth. In the near future, Europe and Asia Pacific are likely to emerge as two of the fastest growing markets.
Growth of the cigars and cigarillos market in Asia Pacific is driven by the increasing demand in China.
Reply:
Jaymac45,
Wow!....Talk about Confidence there.
I love it!
Jaymac45 Thursday, 03/09/17 03:39:11 AM
Re: OTCPennyPincher post# 23740
Post #
23757
of 23758 Go
I'm holding , flippers flip, I'll keep adding from my other profits, sanp is my stock savings account
Reply,
StockPro72,
With that move to 0.003..from..0.0001 and that Bullish News Update PR to go with it on Weds,....Anything is possible now!
Smiles!
STOCKPRO72 Wednesday, 03/08/17 10:34:07 PM
Re: None
Post #
23756
of 23757 Go
Let get it done FRANK .
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=127346858
SANP
Reply:
Whitie,
I like how you think!....Smiles
My goodness, if OTCPennyPincher is correct.....the possibilities!
whitie Member Level Wednesday, 03/08/17 09:00:52 PM
Re: OTCPennyPincher post# 23740
Post #
23749
of 23749 Go
Makes perfect sense to me.
Just a future note:
Buy Volume: 209,870,842
Sell Volume: 183,349,102
Unknown Volume: 2,950,000
Trade Volume: 200,000
Number of Trades: 176
Share Price went to $.0003.......and holding.
The $SANP Run
For....3/8/2017
We need a good SANP After Action Analysis for today: 3/8/2017.
All comments appreciated, whether pro or con.
Looking forward to those sales/revenue PRs.
PJC1 Wednesday, 03/08/17 01:20:39 PM
Re: None
Post #
23727
of 23744 Go
Nice volume, the power of manipulation
This is going nowhere but congrats to those that doubled up
Reply:
Mistr Tommy
Now that is hot news. Keep us Pro-Positive Investors abreast please.
Mistr Tommy Wednesday, 03/08/17 10:00:55 AM
Re: None
Post #
23664
of 23742 Go
The company has been approached by a private company in one of the hottest sectors in the public markets that wishes to go public though SANP. SANP plans on updating its shareholders and the markets in regards to this potential merger in the coming days. $SANP
Look at all these pro-positive investors on this SANP board..!!
It....is....Beautiful..!!
I love Bullish(Positive) news..!
Like a Sinking Ship, this stock is.
ash111 Member Level Friday, 03/03/17 01:31:07 PM
Re: None
Post #
30034
of 30194 Go
drooping like a stone.
Reply:
integral,
If BHTG didn't hire behind the scenes to 3rd partys like Top Nasdaq Stocks and Woodgrove Enterprise, BHTG could bring a lawsuit for false advertising, etc. against them.
On another hand.....if BHTG knowingly was aware of this promotion(scam).....that would make them accomplice to it.
If that is true, that would make BHTG.....scammable and untrustworthy. Why would anyone want to invest in BHTG then?
intergral,....I'm assuming you think BHTG is a solid company and this promotion(scam) was unknowing to BHTG and your wondering when BHTG will file lawsuit against these scammers who advertised false information against BHTG?
Am I wrong or is it something else...?
integral Member Level Friday, 03/03/17 10:35:00 AM
Re: Maker13 post# 14
Post #
17
of 17 Go
Not an article, it is paid for spam:
Quote:
PURSUANT TO AN AGREEMENT BETWEEN US AND WOODGROVE ENTERPRISE, A NON AFFILIATE THIRD PARTY WE WERE HIRED FOR A PERIOD BEGINNING ON 2/21/17 AND ENDING ON 3/21/17 TO PUBLICLY DISSEMINATE INFORMATION ABOUT (BHTG) INCLUDING ON THE WEBSITE AND OTHER MEDIA INCLUDING FACEBOOK AND TWITTER. WE ARE BEING PAID $50,000 (CASH). WE OWN ZERO SHARES
OF (BHTG), WHICH WE PURCHASED IN THE OPEN
MARKET. WE PLAN TO SELL THE “ZERO” SHARES
OF (BHTG) THAT WE HOLD DURING THE TIME THE WEBSITE AND/OR FACEBOOK AND TWITTER INFORMATION RECOMMENDS THAT INVESTORS OR VISITORS TO THE WEBSITE PURCHASE WITHOUT FURTHER NOTICE TO YOU. WE MAY BUY OR SELL ADDITIONAL SHARES
OF (PSTI) IN THE OPEN
MARKET AT ANY TIME, INCLUDING BEFORE, DURING OR AFTER THE WEBSITE AND INFORMATION, PROVIDE PUBLIC DISSEMINATION OF FAVORABLE INFORMATION.
Stockscience,
Thank you so much!
Stockscience Thursday, 03/02/17 11:01:14 PM
Re: BoilerRoom post# 29797
Post #
29798
of 29799 Go
I honestly don't know what should come of a Class-Action Lawsuit against DRYS...I had the impression that someone was interested in preventing another RS and wanted to hang GE out to dry. How minor shareholders can benefit, I have no idea. I suspect there is more going on that what I was told. I will update everyone as I continue to investigate.
OMG!!!!
Stockscience,...you are a heaven sent!!
I have not been contacted by any law firm (yet).
Please keep everyone up-to-date on this. I'd really appreciate it!
"I am told that there is going to a press release to announce this class-action suit that stops GE from further dilution until he can establish that it is in best interest of the minority shareholders as well."
Stockscience Thursday, 03/02/17 10:49:08 PM
Re: None
Post #
29795
of 29795 Go
Hi All,
Yes, I'm still around and I took a loss on my long position. However, I have something interesting happen and I am wondering if I am alone. I was contacted by a someone that represents a law firm that is interested in filing a class action suit against the CEO (GE) of Dryship. Specifically, there are individuals (with far more money to play with than I have) that represent minority shareholders of DRYS that interested in putting a stop to further RS dilution. Evidently, there are laws to prevent this kind of activity to protect shareholders. Look under "anti-dilution" provisions.
http://walkercorporatelaw.com/startup-issues/what-are-the-rights-of-minority-stockholders/
I am told that there is going to a press release to announce this class-action suit that stops GE from further dilution until he can establish that it is in best interest of the minority shareholders as well. So, if this is true, I am guessing that a few investors here might also be contacted. PM me if anyone hears anything of substance.
Maybe there is hope for the longs yet!
Good luck all!!!
We're right!!!.....it is a penny stock (by definition of a penny stock). And you know what....it would be better that DRYS was on the OTC Exchange.
Ya know why?.....So they wouldn't have to worry about doing a REVERSE SPLIT with Investor's shares/money....instead of worrying about the NASDAQ's minimum price bid rule!!!
Penny stock Definition:
In the past, penny stocks were stocks that traded for less than a dollar per share.
The SEC, however, has modified the definition to include all shares trading below $5.
http://www.investopedia.com/terms/p/pennystock.asp
stoprun Thursday, 03/02/17 09:53:32 PM
Re: None
Post #
29783
of 29783 Go
You people area treating this like it is a penny-stock, it has to be listed on NASDAQ
and been in business for years, think about where it might be three to six months from now, very likely much higher, after MM's and shorty gets done playing with this stock. Buy Low and sell High.
YIPES!!!!!!!!!!!!!!!!!!!!!YIPES!!!!!!!!!!!!!!!!!!!!!YIPES!!!!!!!!!!!
01/23/2017 08:07:54 MANDATORY REVERSE SPLIT (DRYS)
01/23/2017 08:07:54 MANDATORY REVERSE SPLIT (Y2109Q309)
Must be nice for you.
Questions?
doj53 Thursday, 03/02/17 08:46:36 PM
Re: None
Post #
29767
of 29780 Go
THERE IS NO R/S ANY TIME THIS YEAR .
I could not agree more. The more the stock share price falls to $1.00, the faster the 2nd R/S for the year will commence. That Dividend Plan looks to be a complete failure.
Question for this board?
How much does it cost to transfer to the NYSE, Composite, or OTC Exchange,.etc?
This minimum price bid for the NASDAQ is the bane of investors for that exchange.
I got hurt on that last R/S btw.
RickNagra Member Level Thursday, 03/02/17 05:43:49 PM
Re: None
Post #
29745
of 29748 Go
Is the reverse split tonight or tomorrow ?
Errrr....yeah. Lets see what's in store for tomorrow. A sales/revenue PR could help things out, I suppose.
TenKay Member Level Thursday, 03/02/17 04:10:20 PM
Re: Maker13 post# 9416
Post #
9425
of 9425 Go
Not so big a day...
Small Cap Leader is promoting PTOTF for Thursday, 3/2/2017
Lets see what happens.
Patriot One Technologies Inc. (PTOTF) is our new alert and we believe this company has strong potential with their breakthrough technology. Patriot One (PTOTF) is a security technology company that is commercially developing portable devices to assist police and civilian personnel to detect concealed weapons utilizing novel radar technology. Patriot One Technologies is dual-listed on the OTCQB (PTOTF) and the TSXV (PAT.V) in Canada.
Patriot One (PTOTF) has developed a first-of-its-kind Cognitive Microwave Radar concealed weapons detection system as an effective tool to combat active shooter threats before they occur. Designed for cost-effective deployment in weapon-restricted buildings and facilities, NForce CMR1000 can be installed in hallways and doorways to covertly identify weapons and to alert security of an active threat entering the premises.
By using their breakthrough Cognitive Microwave Radar technology, PTOTF is able to detect concealed weapons without line of sight. The technology enables them to install their NForce CMR1000 weapons detection system in a wall, floor, or ceiling and send a microwave pulse that detects any metallic device. This information is then sent to their signature database of weapons that analyzes the frequency that comes back and matches it to a weapon in their database. With this, PTOTF can detect guns, knives, vests, and explosives such as grenades.
This technology could be groundbreaking. PTOTF is currently in the commercialization process doing pilots and demonstrations. The technology was developed over eight years at McMaster University(ranked in the top four of all Canadian universities). PTOTF and its research partners contracted through McMaster University are now taking the final steps towards commercial release of this groundbreaking threat detection technology.
On January 17, 2017, Patriot One announced that its NForce systems are scheduled for pilot installation at VGroup Concepts entertainment properties in Orlando
Below is an excerpt from the release:
"The partnership will create a demo showcase of the Company's NForce CMR1000 software solution and radar device from January 2017 through January 2018. The parties furthermore agreed to install the NForce CMR1000 solution and radar device at VGroup entertainment properties around the Orlando area before the end of the term with the ultimate goal of establishing a "safe districts" initiative.
"The Events of June 12, 2016 at the Pulse Nightclub are forever etched in the hearts and minds of the citizens of Orange County, the United States, and the World. It was the deadliest attack by a single shooter in United States History. Our partnership with Patriot One is a positive step toward our goal of making, and continuing to make, the City of Orlando, Orange County, Florida, its residents and all of our visitors safe in the tourist entertainment capital of the world," said VGroup Concepts Operating Managing Partner, Jeff Gitto.
Mr. Gitto is also a founder and active member of the Church Street Revitalization project for Downtown Orlando; through a joint venture focused primarily on the Church Street Entertainment District. In addition, Gitto is a named stakeholder to the City of Orlando Nightclub Task Force charged with making the city's entertainment district as safe as it is vibrant, which drives him to seek out new safety and security solutions for the community and business owners, and which helped lead him to Patriot One's NForce CMR1000 solution.
Martin Cronin, CEO & Director of Patriot One Technologies, Inc. notes, "We are very excited to partner with VGroup Concepts with our NForce CMR1000 pilot program, and to further help the City of Orlando, Orange County, and the great State of Florida's desire to create the world's safest entertainment center. Our number-one goal at Patriot One is to offer a solution that works with today's security professionals to help deter, detect and defend against active threats of violence on innocent citizens everywhere.""
Read the full release from Yahoo Finance
Current security technologies have issues for many reasons including Privacy and Health concerns, requires subject compliance, operator errors and false positives are common, and requires individual processing that lead to slow and inefficient results.
Patriot One's (PTOTF) disruptive technology could eliminate all of these issues. Now let's learn more about their first-of-its-kind covert screening device, the NForce CMR1000.
NForce CMR1000 is an easily concealed, cost-effective and non-invasive full body scanning technology that is proven, practical and safe.
NForce CMR1000 is the world’s most advanced technology for covert screening and detection of concealed weapons. CMR1000 identifies threats by database comparison of known weapons profiles, and by detection of concealed irregular object mass. Unlike millimeter wave units in use currently, the CMR1000 is far less expensive, easily concealed, and utilizes a single scan for detection, as compared to the numerous scans required by large, expensive and manned static installations.
The CMR1000 screens individuals in real time as they pass though the CMR1000 detection field in access points, halls and entryways. Installation can be covert and eliminates the style, look, and feel of institutional metal detectors. NForce`s patent-pending Cognitive Microwave Radar employs a network-wide ability to “learn” and adapt to new threats as “signature” patterns are identified. Pattern updates are transmitted network-wide offering an ever increasing signature library.
Patriot One's NForce detector could be a game changer in security technology and may be the only widely deployable technology in existence that can stop attacks before they get started.
Tom Ridge, America’s first cabinet-level Secretary of Homeland Security appointed by President George W. Bush, now endorses and supports global deployment of Patriot One Technologies’ weapons detection technology, calling it: “Disruptive” technology that should be “of interest to everybody, not just the Department of Homeland Security.” Take a view minutes to hear his comments on Patriot One's weapons detection technology in this video.
Today, Mr. Ridge is regarded as one of the world’s leading experts on counter-terrorism and public security. He founded and is current CEO of Ridge Global LLC, serving government and private interests worldwide in defense against terrorism and security risks. In fact, Patriot One has retained Ridge Global (led by Tom Ridge) to fast track Patriot One into America’s security markets. Tom Ridge could leverage his extensive domestic and global connections to quickly propel Patriot One Technologies to a dominant market presence.
On top of this, according to a recent research by MarketsandMarkets, the security and surveillance radar markets are expected to grow at a CAGR rate of 5.97% and reach $8.61B in value by 2020.
Recent Developments
February 22, 2017- Patriot One Provides NForce CMR 1000 Software Solution and Related Hardware Product Update
Excerpt Below:
"Patriot One is pleased to announce that its NForce CMR1000 software solution and related hardware, has completed internal quality assurance in preparation for a major trade exhibition in April.
The hardware already carries the "CE Mark" which certifies that the product has met EU health, safety and environmental requirements that ensure consumer and workplace safety and allows manufacturers to circulate industrial products freely within the internal market of the EU. The system is now entering pre-certification testing for FCC compliance ahead of its product launch at ISC West (International Security Conference) in Las Vegas in April. The product has also been vetted as ready for inclusion in the prestigious New Product Showcase at that conference.
Patriot One is now optimising its software to enhance performance characteristics and continues to collect additional weapons "signatures" for entry into the NForce proprietary database library. This is being achieved through an extensive law enforcement network which provides controlled access to weapons collections globally. The Company also advised today that it has now identified a manufacturer in the USA that has the capacity to meet the initial demand forecasts of its NForce CMR1000 production needs through 2018.
"One of the most noticeable recent developments is a sleek new profile which will enable greater installation versatility in the field," notes Dinesh Kandanchatha, President and CTO of Patriot One Technologies Inc.
In addition, Patriot One has recently developed valuable new IP regarding antenna design, which will result in the filing of additional patents further protecting its technological advantage in the marketplace.""
Read the full release from Yahoo Finance
February 16, 2017- Patriot One Selected for New Product Showcase by Security Industry Association at ISC West
February 8, 2017- Patriot One Appoints Tech Sector Financial Professional as CFO
January 17, 2017- Patriot One to Commence Onsite Weapons Detection Pilot Tests in Orlando, Florida
Patriot One (PTOTF) could be well on its way to making waves in security technology so make sure to start your research. You can learn more about Patriot One Technologies from their website.
Sincerely,
???????
Small Cap Leader
Pennystock Hub is promoting RGBP for Thursday, 3/2/2017
Lets see what happens.
Today's (3-2) featured company, Regen BioPharma Inc. (RGBP) , has found itself doing discovery phase arrangements with one of the BIGGEST companies in the industry! It just so happens that the industry RGBP is in, is the Biotech space; one of the hottest and most active sectors of the market today!
RGBP Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company!
In case you're not familiar, Eli Lilly and Company is an $88Billion company, publicly trading RIGHT NOW at roughly $84/share..why would a company like this even be in the same room as (RGBP) ? In our opinion, the answer is opportunity.
The two companies entered into a definitive agreement with Eli Lilly and Company, which allows (RGBP) to receive compounds from Lilly for drug discovery purposes and allows (RGBP) to share structural information on compounds of mutual interest.
The agreement also grants to Lilly an option to negotiate an agreement with Regen including but not restricted to a compound purchase agreement, a license agreement, or a research collaboration agreement for further research and development of material of mutual interest.
Could (RGBP) Be Setting Up For A Major Move In The Very Near Term?
(RGBP) is working to develop immunotherapies and cancer stem cell therapies for rapid commercialization. The Company is specifically focused on human therapies that address unmet medical needs. (RGBP) has already begun the process of optimizing its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02, which are inhibitors and activators of NR2F6; potentially a very important immune cell inhibitor or checkpoint & specialized cancer stem cell.
Basically (RGBP) is working to identify what interferes with NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system...did we mention that one of the biggest companies in biotech has tapped (RGBP) in order to further the investigation and to identify activators and inhibitors of this NR2F6 protein?
Eli Lilly has been behind some of the most famous medical developments out there and we're willing to bet that you've heard of them: Cymbalta...Prozac...what about Cia lis? And now we're looking at a micro-cap company aligned directly with this company through this discovery program!
Issued US Patent # 9091696 was granted to (RGBP) and covers means of screening small molecules such as is being done in this program.
Cancer, as well as autoimmune diseases such as lupus, rheumatoid arthritis and irritable bowel syndrome, is likely to be controlled by modifying NR2F6 activity according to the company.
Market For Immunotherapy Drugs: $201 Bil. by 2021
According to ResearchAndMarkets, the global immunotherapy drugs market is projected to reach $201.52 Billion by 2021 from $108.41 Billion in 2016, a compounded annual growth rate of 13.5% during the forecast period of 2016 to 2021.
North America is expected to account for largest share in the immunotherapy drugs market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.
And as far as cancer immunotherapy, that market alone is projected to reach $119.39 Billion by 2021!
Project Pipeline Already Has The Attention Of The FDA
If you have seen other small cap biotechs, their pipelines may be small, one therapy at times. Not only does (RGBP) have multiple treatments in their pipeline but they've already received clearance to proceed to PHASE I / II CLINICAL TRIALS!
HemaXellerate Aplastic
Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow and has its Investigational New Drug Application already cleared by the ?United States Food and Drug Administration cleared (IND #15376)
dCellVax
Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
DiffronC
Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
Small Molecule Targeting Cancer Stem Cell Genes
Small Molecule targeting of the cancer stem cell is the process of “coaxing” the cancer stem cell to turn into a normal cell. Regen has identified and filed patents on a novel gene controlling the process of cancer stem cell differentiation.
Telomeres & Genomic Integrity
Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
Bottom Line
A company like this doesn't come around every day. For such a small company to be on the radar screen of a "Big Boy Biotech" is one thing but to be directly working alongside a powerhouse like Eli Lilly could put (RGBP) head and shoulders above its competition.
Not only does the company have an active pipeline with Phase trials potentially right on the horizon but future possibilities for licensing and beyond could be key indicators signaling that this could be one of the smaller cap biotechs to be watching right now!
We want to stress that being ready at the opening bell could be key to watching for a potential breakout, especially with a biotech alert like this. These can become active right out of the gate and it all starts at 9:30AM EST on Thursday (3-2). So if you choose, pull up (RGBP) , do your DD, and be ready for the opening bell, this morning (3-2)! Stay tuned.
Want Instant Updates on Our Alerts?
PURA PPS On Verge Of Breakout Back To Recent $0.09 High After Pending Short Cover
http://ih.advfn.com/p.php?pid=nmona&article=73986554&symbol=NO%5EUSMJ
Dallas, TX – March 1, 2017 – Wall Street Corner Report
Puration, Inc. (USOTC: PURA) is on the verge of a PPS breakout as a month of short sellers attempting to cover comes to an end. On February 2, PURA was one of the most shorted stocks on the OTC. Again, on February 22, PURA was one of the most shorted stocks. Short sellers have continued all month to sell short every day (see chart below) in an effort to hold back the PPS and cover their short positions. Short sellers have found now eager sellers willing to give up long-term positions.
Between the short selling to hold back the PPS and the high volume short selling on the 2nd and the 22nd, short sellers have failed to cover their positions.
February has ended and the shorts are on borrowed time. Month end reconciliations are coming and so is the buy-in to cover their outstanding short positions.
Stock Technical Analysis (stockta.com) continues to rate PURA BULLISH in the long-term making the outlook for short sellers even more bleak. Hold on to your hat and get ready to see the PURA PPS breakout above $0.06 and reach previous highs of $0.09.
Top Ten Most Shorted Stocks Also Include:
North American Cannabis Holdings, Inc. (USOTC: USMJ)
Vapor Group (USOTC: VPOR)
American Green (USOTC: ERBB)
Wall Street Corner Report is the premier discovery site for promising, yet undiscovered small and micro-cap stocks featuring opportunities in an ethical, professional, and responsible manner. We're not fiendishly 'short' sighted nor are we here to dream the impossibly 'long' dream. We take a practical view on the big ideas of well-intentioned management and look to profit on each reasonably achievable step the well intentioned mangers take toward their big ideas.
http://www.wallstreetcornerreport.com/more-news/
https://twitter.com/WallStCornerRpt
PURA PPS On Verge Of Breakout Back To Recent $0.09 High After Pending Short Cover
http://ih.advfn.com/p.php?pid=nmona&article=73986554&symbol=NO%5EUSMJ
Dallas, TX – March 1, 2017 – Wall Street Corner Report
Puration, Inc. (USOTC: PURA) is on the verge of a PPS breakout as a month of short sellers attempting to cover comes to an end. On February 2, PURA was one of the most shorted stocks on the OTC. Again, on February 22, PURA was one of the most shorted stocks. Short sellers have continued all month to sell short every day (see chart below) in an effort to hold back the PPS and cover their short positions. Short sellers have found now eager sellers willing to give up long-term positions.
Between the short selling to hold back the PPS and the high volume short selling on the 2nd and the 22nd, short sellers have failed to cover their positions.
February has ended and the shorts are on borrowed time. Month end reconciliations are coming and so is the buy-in to cover their outstanding short positions.
Stock Technical Analysis (stockta.com) continues to rate PURA BULLISH in the long-term making the outlook for short sellers even more bleak. Hold on to your hat and get ready to see the PURA PPS breakout above $0.06 and reach previous highs of $0.09.
Top Ten Most Shorted Stocks Also Include:
North American Cannabis Holdings, Inc. (USOTC: USMJ)
Vapor Group (USOTC: VPOR)
American Green (USOTC: ERBB)
Wall Street Corner Report is the premier discovery site for promising, yet undiscovered small and micro-cap stocks featuring opportunities in an ethical, professional, and responsible manner. We're not fiendishly 'short' sighted nor are we here to dream the impossibly 'long' dream. We take a practical view on the big ideas of well-intentioned management and look to profit on each reasonably achievable step the well intentioned mangers take toward their big ideas.
http://www.wallstreetcornerreport.com/more-news/
https://twitter.com/WallStCornerRpt
PURA PPS On Verge Of Breakout Back To Recent $0.09 High After Pending Short Cover
http://ih.advfn.com/p.php?pid=nmona&article=73986554&symbol=NO%5EUSMJ
Dallas, TX – March 1, 2017 – Wall Street Corner Report
Puration, Inc. (USOTC: PURA) is on the verge of a PPS breakout as a month of short sellers attempting to cover comes to an end. On February 2, PURA was one of the most shorted stocks on the OTC. Again, on February 22, PURA was one of the most shorted stocks. Short sellers have continued all month to sell short every day (see chart below) in an effort to hold back the PPS and cover their short positions. Short sellers have found now eager sellers willing to give up long-term positions.
Between the short selling to hold back the PPS and the high volume short selling on the 2nd and the 22nd, short sellers have failed to cover their positions.
February has ended and the shorts are on borrowed time. Month end reconciliations are coming and so is the buy-in to cover their outstanding short positions.
Stock Technical Analysis (stockta.com) continues to rate PURA BULLISH in the long-term making the outlook for short sellers even more bleak. Hold on to your hat and get ready to see the PURA PPS breakout above $0.06 and reach previous highs of $0.09.
Top Ten Most Shorted Stocks Also Include:
North American Cannabis Holdings, Inc. (USOTC: USMJ)
Vapor Group (USOTC: VPOR)
American Green (USOTC: ERBB)
Wall Street Corner Report is the premier discovery site for promising, yet undiscovered small and micro-cap stocks featuring opportunities in an ethical, professional, and responsible manner. We're not fiendishly 'short' sighted nor are we here to dream the impossibly 'long' dream. We take a practical view on the big ideas of well-intentioned management and look to profit on each reasonably achievable step the well intentioned mangers take toward their big ideas.
http://www.wallstreetcornerreport.com/more-news/
https://twitter.com/WallStCornerRpt
Finally.....tomorrow is the BIG DAY!
I hope all fellow pro-positive investors a hopeful and....Bullish day tomorrow.
USMJ
PURA
MLCG
ALKM
* May the pro-positive investors wipe out the short sellers.
Finally.....tomorrow is the BIG DAY!
I hope all fellow pro-positive investors a hopeful and....Bullish day tomorrow.
USMJ
PURA
MLCG
ALKM
* May the pro-positive investors wipe out the short sellers.
Finally.....tomorrow is the BIG DAY!
I hope all fellow pro-positive investors a hopeful and....Bullish day tomorrow.
USMJ
PURA
MLCG
ALKM
* May the pro-positive investors wipe out the short sellers.
Finally.....tomorrow is the BIG DAY!
I hope all fellow pro-positive investors a hopeful and....Bullish day tomorrow.
USMJ
PURA
MLCG
ALKM
* May the pro-positive investors wipe out the short sellers.
Dividend Plan works or Another R/S?
Alright guys, I posted this on another board. Give me all your humble opinions.
Looking at that share price right now: $1.87,...the share price has been shrinking back down again (towards $1.00). If that happens again DRYS is going to have to do another R/S.
That last R/S at the beginning of 2017 nearly gave me PTSD....because the share price fell well below my buy price before the R/S.
If they do another R/S again.... OMG . This Dividend Plan better work....or the share price is going to keep on shrinking toward $1.00....again.
Just look at DRYS Jan - Feb chart.
Talk about a 50/50 chance here.
Whataya think?
$DRYS: NEWS! DryShips Inc. Announces the Initiation of a Regular Quarterly Dividend Policy and Declares Its First Dividend to Holders of Common Stock Under the New Policy
Published: Feb 27, 2017 4:05 p.m. ET
ATHENS, GREECE, Feb 27, 2017 (Marketwired via COMTEX) -- ATHENS, GREECE--(Marketwired - Feb 27, 2017) - DryShips Inc. DRYS, -16.52% (the "Company" or "DryShips" , a diversified owner of ocean going cargo vessels, announced today that its Board of Directors has decided to initiate a new dividend policy. Under this policy, the Company will pay a regular fixed quarterly dividend of $2.5 million to the holders of common stock. In addition, at its discretion, the Board may decide to pay additional amounts as dividend each quarter depending on market conditions and the Company's financial performance, over and above the fixed amount.
With respect to the quarter ended December 31, 2016, the Board of Directors declared a dividend of $2.5 million to the common shareholders of record as of March 15, 2017 and payable on or about March 31, 2017. The dividend per share amount to be paid by the Company will be determined based on the number of shares outstanding on the record date.
George Economou, the Company's Chairman and Chief Executive Officer, commented:
"We are very excited to initiate our new dividend policy which is a testament to the dramatic transformation of the Company's finances over the last 6 months. We continue to transform DryShips and we are confident that the results of our efforts will become evident in the near future."
Good Article on BHTG from Top Nasdaq Stocks.
http://topnasdaqstocks.com/index.php/2017/02/22/something-not-even-donald-trump-can-ignore/
OTC Profiler is promoting PTLF for Tuesday, 2/28/2017.
Lets see what happens..again.
* Last one was on 2/21/2017
PTLF Is On HIGH ALERT!
My New Monster Pick for Tuesday is: PTLF
I am once again bringing you a known play for Monster Runs - PTLF!
PTLF is no stranger to Monster Runs, last week it ran from .201 to .90 cents representing 347% Gains and back in July it ran from .17 cents to 1.00. I now believe its setting up for another Monster Run.
Symbol: PTLF
Co: PetLife Pharmaceuticals, Inc.
Breakout Catalyst: (+)
PTLF Is On Immediate ALERT!
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals, under its new tradename VitalzulTM, based on the same patented formula "Escozine" and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
PTLF Operates In the Booming $62B Pet Health Industry!
PTLF is poised to change the paradigm of treatment in veterinary oncology. It is reported that over 50% of dogs and cats living past the age of 10 develop cancer. Last year in the U.S. approximately 13 million families had to face this diagnosis in their beloved companion animals. Our all natural "Vitalzul for Pets™ has a strong scientific basis for the treatment of cancer and offers an alternative to standard chemotherapy, surgery and other invasive treatment that are often as toxic as the cancer itself. PetLife's mission is to provide an affordable solution that also avoids the unfortunate and often deadly side effects of traditional treatment.
PetLife Pharmaceuticals is introducing a new break through pet cancer drug that is anticipated to begin FDA trials this summer. The drug is an organic-all natural compound. The FDA trials are estimated to take no longer than 18-24 months.
With pets living longer than ever, cancer is becoming a serious problem.
Cancer is the # 1 disease related cause of death for dogs in the U.S.
Cancer accounts for almost 50% of deaths in pets older than 10 years Average costs to treat lymphoma in pets is $2,000-most owners will rather watch their pets die than pursue treatment 1 in 4 dogs and 1 in 5 cats will develop cancer in their lifetime.
Dogs get cancer at about the same rate as humans
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of HP (high potency) veterinary cancer medications and nutraceuticals, based on the same patented formula "Escozine" and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
Given the histology (the similarity of the cellular biology) between humans and dogs and cats and the growing body of new preclinical research (UCSD) establishing the effectiveness of Escozine for the treatment of animals, PetLife has licensed the worldwide rights to formulate, package and market a new product line, "Escozine for PetsTM."
The Company's products have been demonstrated as a preventative and a treatment of cancer, and to dramatically improve the quality of life, and extend the longevity of pets with cancer -- without the painful, debilitating side effects of toxic, conventional chemotherapy.
Investor Highlights
PetLife Pharmaceuticals has licensed the worldwide rights to formulate, package and market a new product line, "Escozine for Pets™.
In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
62% of American households include at least one pet.
PetLife Pharmaceuticals Just Announced Huge News of New Chairman of Product Development and Advisory Board World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick
Virtually undiscovered company with ground floor opportunity with a unique product that has the potential to prevent and treat cancer and to dramatically improve quality of life and extend the longevity of pets with cancer -- without the harmful side effects of conventional chemotherapy and other traditional treatment programs.
PTLF is one exciting stock with a powerhouse management team!
PTLF has taken huge steps forward recently, placing the Company in an excellent position for growth.
Pay close attention because this is the EXACT "Catalyst" that could ignite this tiny stock into new levels.
PTLF just announced that it has retained Gregory FCA Communications, Inc., one of the nation's largest public relations agencies, to help bring to market a breakthrough cancer treatment for pets produced from the venom of the blue scorpion.
============================
NOTE: This is the exact catalyst needed to give PTLF the edge
and potentially trade much higher in the next couple weeks!
============================
They also just announced HUGE News that they have appointed World Renowned Dr. R. Geoffrey Broderick as the Chairman of Product Development and Advisory Board all of which indicate the Company's Huge Growth potential!
Dr. Broderick, one of the world's most famous veterinarians, comes to PetLife Pharmaceuticals with an intricate knowledge of the pet industry, he is a practicing veterinarian with over 48 years' experience as an international expert, and is also a professional developer of organic pet food, pet supplements, and other pet products, including the first natural pet food, the first snack for senior dogs, the first dietary formula, and the first antioxidant supplement.
Besides these preventative revolutionary inventions, he also prevailed in his veterinary career with many awards and other accreditations. He was the first in history to dissolve urinary stones without antibiotics, for which he is the recipient (and the youngest to ever receive) the Award by the Committee for World Health, which was presented on the 50th anniversary for the discovery of Vitamin C (in Palm Springs CA, 1978). In fact, this revolutionary work was eventually incorporated in his subsequently developed Cornucopia Natural Pet Products in order to provide the proper PH of urine to prevent struvite (triple phosphate) urinary stones from happening in the first place.
Bottom Line...
PTLF is a unique opportunity in an expanding $62 Billion Dollar Industry and we think you should take a serious look at this company!
Wall Street is about to Show Major Interest in PTLF!
Remember PTLF is no stranger to big moves, back in July it ran from .17 cents to 1.00. - Then we just witnessed it fly from .20 cents to .90 cents last week...
I now believe its setting up for another Monster Run to radical new levels sending shock waves through Wall Street tomorrow as investors potentially scoop up huge amounts of cash!
Best Regards,
The OTCprofiler Team
OTC Profiler is promoting BKIT for Monday 2/27/2017.
breakawaystocks.com/bkit/index.html
Let's see what happens.
* Correction on Date Year.
It makes you wonder how successful Erik Prince will become? Watching that share price.
OTC Profiler is promoting BKIT for Monday 2/27/2016.
breakawaystocks.com/bkit/index.html
Let's see what happens.
Reply:
Goodness...what is going on with this stock? Hmmmmmm.
What you would never think..is. What you would think...isn't.
lol
TradeForProfits Member Level Thursday, 02/23/17 02:00:42 PM
Re: Maker13 post# 2584
Post #
2595
of 2595 Go
sadly I was wrong... $0.90 today LOL. go ptlf go
Reply:
TradeForProfits,
What do you think we're looking at by next week with the share price? Best guess.
TradeForProfits Member Level Wednesday, 02/22/17 12:28:57 PM
Re: Maker13 post# 2576
Post #
2582
of 2583 Go
$PTLF up 22% from close. Continues to build ahead of 2nd pre-INAD study results.
Reply:
marina22
Ahhhh no, that's not what I'm saying. If everything followed and went accordingly to the fundamentals, investors could predict every move, no matter what.
I did not predict either way what would happen to the share price because of the promotion. Some promotions fail, and some do not. The Promotion nevertheless helped to gain attention. I would say that's at least a fair statement.
What Awl416 said, (in regards to the low volume yesterday) seems to be the constant here, half jokingly saying.
It makes you wonder if the buying volume went over a Million yesterday, what would've the share price have done?
Awl416 "Considering the volume someone wants this higher"
marina22 Wednesday, 02/22/17 03:49:09 AM
Re: Maker13 post# 2576
Post #
2578
of 2582 Go
are u saying fundamentals are bad that thre rise happened only due to the [promotion?
Agreed.
Yeah...this promotion was successful, to say the least. I hope you and other investors made out....at least some. Congrats to PTLF investors today.
OTC Profiler is promoting PTLF for: Tuesday 2/21/2017
Lets see what happens.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of potentiated veterinary cancer medications and nutraceuticals, under its new tradename VitalzulTM, based on the same patented formula "Escozine" and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
PTLF Operates In the Booming $62B Pet Health Industry!
PTLF is poised to change the paradigm of treatment in veterinary oncology. It is reported that over 50% of dogs and cats living past the age of 10 develop cancer. Last year in the U.S. approximately 13 million families had to face this diagnosis in their beloved companion animals. Our all natural "Vitalzul for Pets™ has a strong scientific basis for the treatment of cancer and offers an alternative to standard chemotherapy, surgery and other invasive treatment that are often as toxic as the cancer itself. PetLife's mission is to provide an affordable solution that also avoids the unfortunate and often deadly side effects of traditional treatment.
PetLife Pharmaceuticals is introducing a new break through pet cancer drug that is anticipated to begin FDA trials this summer. The drug is an organic-all natural compound. The FDA trials are estimated to take no longer than 18-24 months.
With pets living longer than ever, cancer is becoming a serious problem.
Cancer is the # 1 disease related cause of death for dogs in the U.S.
Cancer accounts for almost 50% of deaths in pets older than 10 years Average costs to treat lymphoma in pets is $2,000-most owners will rather watch their pets die than pursue treatment 1 in 4 dogs and 1 in 5 cats will develop cancer in their lifetime.
Dogs get cancer at about the same rate as humans
PetLife Pharmaceuticals, Inc. (PetLife) has developed and is launching a new generation of HP (high potency) veterinary cancer medications and nutraceuticals, based on the same patented formula "Escozine" and production processes that have been scientifically proven as an effective treatment for cancer in humans for years. Escozine (for humans) is currently sold as either a nutraceutical or prescription drug in 40 countries including the US.
Given the histology (the similarity of the cellular biology) between humans and dogs and cats and the growing body of new preclinical research (UCSD) establishing the effectiveness of Escozine for the treatment of animals, PetLife has licensed the worldwide rights to formulate, package and market a new product line, "Escozine for PetsTM."
The Company's products have been demonstrated as a preventative and a treatment of cancer, and to dramatically improve the quality of life, and extend the longevity of pets with cancer -- without the painful, debilitating side effects of toxic, conventional chemotherapy.
Investor Highlights
PetLife Pharmaceuticals has licensed the worldwide rights to formulate, package and market a new product line, "Escozine for Pets™.
In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
62% of American households include at least one pet.
PetLife Pharmaceuticals Just Announced Huge News of New Chairman of Product Development and Advisory Board World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick
Virtually undiscovered company with ground floor opportunity with a unique product that has the potential to prevent and treat cancer and to dramatically improve quality of life and extend the longevity of pets with cancer -- without the harmful side effects of conventional chemotherapy and other traditional treatment programs.
PTLF is one exciting stock with a powerhouse management team!
PTLF has taken huge steps forward recently, placing the Company in an excellent position for growth.
They just announced HUGE News that they have appointed World Renowned Dr. R. Geoffrey Broderick as the Chairman of Product Development and Advisory Board all of which indicate the Company's Huge Growth potential!
Dr. Broderick, one of the world's most famous veterinarians, comes to PetLife Pharmaceuticals with an intricate knowledge of the pet industry, he is a practicing veterinarian with over 48 years' experience as an international expert, and is also a professional developer of organic pet food, pet supplements, and other pet products, including the first natural pet food, the first snack for senior dogs, the first dietary formula, and the first antioxidant supplement.
Besides these preventative revolutionary inventions, he also prevailed in his veterinary career with many awards and other accreditations. He was the first in history to dissolve urinary stones without antibiotics, for which he is the recipient (and the youngest to ever receive) the Award by the Committee for World Health, which was presented on the 50th anniversary for the discovery of Vitamin C (in Palm Springs CA, 1978). In fact, this revolutionary work was eventually incorporated in his subsequently developed Cornucopia Natural Pet Products in order to provide the proper PH of urine to prevent struvite (triple phosphate) urinary stones from happening in the first place.
Bottom Line...
PTLF is a unique opportunity in an expanding $62 Billion Dollar Industry and we think you should take a serious look at this company!
Wall Street is about to Show Major Interest in PTLF!
Remember PTLF is no stranger to big moves, back in July it ran from .17 cents to 1.00. We have seen a few pull backs since followed by big runs, I now believe its setting up for another Monster Run.
If you missed the big moves on my some of my recent big picks, YOU better get busy now and research PTLF and have it pulled up early Tuesday morning.
Best Regards,
The OTCprofiler Team